Search

everythinglearnresearchcommunity

for

Search:↓

Using tamsulosin and finasteride together for benign prostatic syndrome has increased and shows improvement in symptoms, but more reliable comparisons are needed.

CAG repeat polymorphism and prostate zone volume are not reliable markers of long-term androgen sensitivity.

Dutasteride may help prevent prostate cancer, but more research is needed.

Finasteride lowers risk of urinary issues and surgery by over 50% in 4 years.

Five-alpha reductase inhibitors, like finasteride and dutasteride, can treat enlarged prostates, improve urination, reduce need for prostate surgery, and lower the risk of prostate cancer, but may increase the risk of higher grade prostate cancer. They can also treat male pattern baldness.

Certain gene combinations may affect prostate cancer risk, and GSTP1 methylation is linked to tumor aggressiveness.

Combination therapy for BPH is more effective in certain men but may not be cost-effective due to minimal impact and potential side effects.

Low dose finasteride causes only small changes in PSA levels in older men with BPH.

Provenge extends prostate cancer survival by about 4 months.

The root extract of Untica mairei Levl may help treat benign prostatic hyperplasia.

Combination therapy is more effective for prostate volumes over 60 ml.

Taking 5-ARI before prostate laser surgery may lead to more blood changes, longer surgery, and more urinary issues.

No link between hair loss severity and PSA levels in men.

Chronic pelvic pain in men is common, but its cause is unknown and treatments are often ineffective.

Men taking dutasteride may have a higher risk of age-related macular degeneration.

Finasteride effectively treats benign prostatic hyperplasia by reducing prostate size and improving urinary symptoms.

Long-term treatment with finasteride or combined therapy worsens sexual function in men with urinary issues.

Methylated gene parts may cause finasteride-resistance in some enlarged prostate patients.

A stronger dual 5α-reductase inhibitor could improve treatment for benign prostatic hyperplasia by further reducing DHT levels.

COVID-19 may worsen symptoms of benign prostatic hyperplasia (BPH).

Androgens increase norepinephrine release, promoting smooth muscle growth in male sex organs, which may contribute to benign prostatic hypertrophy.

New compounds show promise for treating benign prostate hyperplasia with fewer side effects.

Herbal products for benign prostate hypertrophy need better quality checks to ensure safety and effectiveness.

Platelet-rich plasma can improve erectile function in older individuals by reducing prostate enlargement.

Higher uric acid levels are linked to fewer urinary symptoms in healthy Korean men.

Correct testosterone levels for age to treat prostate cancer, using low dose treatments as necessary.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

Finasteride helps with prostate symptoms but may cause sexual side effects.

Phellodendri Cortex Extract may help treat benign prostatic hyperplasia.

Finasteride effectively reduces prostate size and symptoms in most BPH patients.